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Abstract

TRIPTOLIDE IS A POTENTIAL THERAPEUTIC AGENT FOR ALZHEIMER’S
DISEASE
By Matthew Allsbrook
A thesis submitted in partial fulfillment of the requirements for the degree of Master of
Science at Virginia Commonwealth University.

Virginia Commonwealth University, 2009

Major Director: Dr. Guo-Huang Fan
Assistant Professor, Department of Pharmacology & Toxicology

Mounting evidence indicates an involvement of inflammation in the pathogenesis
of Alzheimer’s disease. While there are other mechanisms involved, it is this role of
inflammatory processes that we wish to investigate. Triptolide is the major constituent in
the Chinese herb, Tripterygium wilfordii Hook F, and has been used for centuries as part of
Chinese herbal medicine. The four ringed structure has close homology to drugs of the
steroid class and it has been shown to be beneficial as an anti-inflammatory for rheumatoid
arthritis and for treatment of certain cancers. The aim of this study was to evaluate the
potential therapeutic effect of Triptolide on the neuropathology and deficits of spatial
5

learning and memory in amyloid precursor protein (APP) and presenilin 1 (PS1) doubletransgenic mice, a well established Alzheimer’s disease (AD) mouse model. After
treatment of APP/PS1 mice with Triptolide (40µg/kg, three times weekly,), initiated when
the mice were 5 months old, for as little as 8 weeks, significant decrease in β-amyloid (Aβ)
deposition and microglia activation was observed. Moreover, Triptolide treatment robustly
rescued spatial memory deficits observed in APP/PS1 mice. However, APP processing, tau
hyperphosphorylation, and the activities of the two major kinases involved in tau
hyperphosphorylation, cyclin dependent kinase 5 (cdk5) and glycogen synthase kinase 3β
(GSK3β) were not affected by the Triptolide treatment. Based on the recent finding for the
inhibitory effect of Triptolide on Aβ-induced production of pro-inflammatory cytokines
from microglia, we propose that Triptolide treatment may have beneficial properties in
halting glial activation and help restore an immune system that fights plaque deposition.
Although the exact mechanism of action has yet to be deduced, the increase in APP CTFs
while having a significant decrease in amyloid plaque deposition suggests that alterations
in gamma secretase activity may be a possible answer. Currently, these results support the
use of Triptolide as an effective therapeutic to prevent the progression of Alzheimer’s
disease.

Key words: Alzheimer’s disease, triptolide, APP processing, microglia, astrocytes
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Introduction

Today, Alzheimer’s disease (AD) is the number one cause of dementia in the
elderly. Dementia refers to a progressive decline in cognitive function due to neuronal
damage that is unlike the normal aging process. As of now, there is no cure and the
degeneration of neurons coupled with secondary complications from sedentary behavior
will eventually lead to the death of the patient. It was first described by Alois Alzheimer in
1901, a German psychiatrist who described his patient as having symptoms of strange
behavior and short-term memory loss. Subsequent examination of the patient’s brain
showed amyloid plaque deposition and neurofibrillary tangles, two major hallmark
pathologies associated with AD. Current treatments consist of acetylcholinesterase
inhibitors (donepezil, galantamine, rivistigmine) and the drug memantine, which is an
NMDA receptor antagonist. The NMDA receptor is an ionotropic glutamate receptor
which when activated will open and allow the flow of cations in and out of the cell.
Synaptic plasticity plays an important role for learning and memory and calcium flux
through the NMDA receptor upon activation is thought to be critical in this process. It is
well known that AD brains show a reduction in cholinergic neuron activity due to
degeneration of these neurons, thus acetylcholinesterase inhibitors are used to increase the
concentration of acetylcholine in the brain, thereby maintaining the activity of cholinergic
neurons. Although hotly debated, some believe that excitotoxicity from excess glutamate is
also a feature of AD and memantine’s activity at NMDA receptors blocks this
7

overstimulation from glutamate. These drugs represent symptomatic treatments, not
mechanistic or cause-based treatment and thus have no indication for delaying or halting
the progression of neurodegeneration. As a side note, part of memantine’s controversial
mechanisms of action are a result of some clinical trials showing that patients receiving
memantine retained cognitive functions longer than those not taking it, suggesting a delay
in the progression of AD.
The need for a definitive treatment that has the ability to halt or delay further
neurodegeneration cannot be emphasized enough. Currently, there are approximately 5
million cases of AD in the United States, costing over $350 billion per year. These
numbers are expected to escalate to over 15 million cases at a cost of over $1 trillion per
year by 2050. This is predicted because the average lifespan has more than doubled since
1840 and furthermore, we face increasing numbers of people over the age of 65 that
require more and more medical care (Figure 1). If nothing is done to reverse and/or treat
this disease, we face an epidemic of neurological diseases that encompass not only AD, but
Parkinson’s, Amyotrophic Lateral Sclerosis (ALS), and many more.

8

Percentage of Older Adults who have Alzheimer's Disease, by Age

Figure 1 Chart reflecting the percentage of adults in the United States who have AD. As the age of the
population increases, the chances of developing AD increases exponentially.

(Figure from http://aspe.hhs.gov/health/Reports/medicalinnovation/, US Dept. of HHS)

APP Processing and the Amyloid Hypothesis
Aβ plaque deposition begins when the amyloid precursor protein (APP), a type I
transmembrane glycoprotein, undergoes endoproteolytic cleavage by β-site APP cleaving
enzyme 1 (BACE1, β-secretase), producing a secreted ectodomain of APP and the C99
membrane-bound fragment of the remaining APP protein. The C99 fragment becomes the
substrate for subsequent cleavage by another protease, γ-secretase, which produces the
carboxyl terminus of Aβ and subsequently, the mature peptide is secreted from the cell to
aggregate with other Aβ peptides to form amyloid plaques. The cleavage by γ-secretase is
9

not always specific and will produce fragments that vary in their amino acid length.
However, the majority of fragments produced by γ-secretase contain either 40 or 42 amino
acids, referred to as Aβ40 and Aβ42. It has been shown that insoluble, oligomeric Aβ40/42
(Jiao, Xue et al. 2008) is more pathologically relevant to the degenerative effects of AD
than other monomers and oligomers of different lengths. Another enzyme involved in
APP processing, α- secretase, cleaves APP in the middle of the Aβ domain which
precludes the formation of Aβ plaques. This can be considered ‘normal’ APP processing
and is referred to as the non-amyloidogenic pathway in APP processing (Vassar 2002).
The importance of BACE1 in the progression of AD is that it has been identified as the
first enzyme that cleaves the APP protein and results in an increase in Aβ deposition. This
may be the initial cause which “gets the ball rolling” in a pathological state. Indeed, the
introduction of BACE1 siRNA through lentiviral vectors has been shown to ameliorate AD
pathologies and neural deficits in vivo (Singer, Marr et al. 2005).

10
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Figure 2 Diagram of APP processing. In the amyloidogenic pathway, sequential cleavage of APP by BACE1
and γ-secretase yields fragments of Aβ 40 and 42, referring to the amino acid length. These dimerize and
oligomerize into amyloid plaques.
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Figure 3 In the non-amyloidogenic pathway, APP is sequentially cleaved by α-secretase followed by γsecretase which yields CTFs and AICD. The cleavage of APP is within the Aβ domain which precludes the
formation of Aβ plaques. This can be thought of as the “normal” processing of APP.

Until recently, the amyloid hypothesis was by consensus the leading theory on which the
research community based their work around. It allowed scientists to focus on a specific
set of pathologies that could possibly yield therapeutic breakthroughs. Part of the reason
that there has been some malcontent among the scientific community regarding the
amyloid hypothesis revolves around the thought that all amyloid oligomers and plaques are
toxic. While Aβ oligomers are clearly implicated in synaptic interruption, it is difficult to
definitively say that Aβ is toxic to neurons since no convincing data has yet to be
presented. Also, reports of successfully clearing of Aβ plaques from mice brains using
immunization techniques does not clearly indicate the effects of Aβ on behavioral changes
12

(Schenk, Barbour et al. 1999). As far as clinical success with immunization techniques, it
was concluded that although successful clearance of Aβ can be achieved, the end result of
a rescue in cognitive function was not guaranteed since late stages of the disease are
irreversible. However, administration of a vaccine or antibodies early in the disease
progression could offer hope in delaying or halting the neurodegeneration (Boche, Zotova
et al. 2008; Hardy 2009). Finally, there is a possibility that a double hit hypothesis is
implicated more in onset of late-onset Alzheimer’s disease (LOAD). It provides a cause for
how neurodegeneration induced by tau hyperphosphorylation appears in LOAD. But, it
still leaves fundamental questions about the relationship between APP/Aβ and tau protein
(Hardy 2009).

Tau hyperphosphorylation
Tau is a microtubule-associated protein abundant in neurons of the CNS and helps
maintain normal neuronal functions, such as axonal transport and neuron stabilization. The
components of microtubules are globular proteins called tubulins that weigh roughly
55kDa. The tubulins come in many forms but the most common forms are the α-tubulins
and β-tubulins. The interaction of tau with these tubulins helps stabilize the microtubule
structure and promote its assembly within the cell. This is beneficial because it permits
neurite expansion. The phosphorylation of tau results in the destabilization of the
microtubule assembly. This results in a breakdown of microtubules that are necessary
stages in many cell cycle functions, including cell division and mitosis. In Alzheimer’s
disease, one of the major hallmark pathologies are aberrant structures of intracellular
13

neural tangles of hyperphosphorylated tau called neurofibrillary tangles (NFTs). NFTs are
composed of tau proteins which aggregate to form structures called paired helical filaments
(PHFs) (Maccioni, Munoz et al. 2001). These are the components to NFTs.
Phosphorylation of tau occurs at more than thirty different serine/threonine residues in the
AD brain by several kinases. Proline-directed kinases include GSK3β, CDK5, p38/MAPK,
and JNK. Non-proline directed kinases include PKA, PKC, CaMKII, and MARK (Avila
2006). Major focus has been towards GSK3β since this kinase has been extensively studied
and characterized under pathological conditions. In familial Alzheimer’s disease (FAD),
there are several mutations in genes that code for proteins clearly implicated in the
facilitation of AD pathologies. These include APP and the presenilin proteins, PS-1 and
PS-2. Missense, deletion, and silent mutations in these genes have each been shown to
result in the corresponding protein’s inability to bind protein phosphatase 2A, an enzyme
responsible for the dephosphorylation of tau (Goedert, Satumtira et al. 2000).
Consequently, the reduced ability to dephosphorylate results in a constitutively
phosphorylated state of the tau protein, which leads to accumulation of NFTs.
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Figure 4 Tau hyperphosphorylation begins when the microtubule associated protein tau is phosphorylated by
several kinases which results in microtubule disassembly and concomitant aggregation of
hyperphosphorylated tau. These form the intracellular NFTs which are neurotoxic.

Amyloid deposition or Tau hyperphosphorylation?
It is still unclear which major hallmark pathology is implicated to exert the more
significant cognitive and memory deficits on the diseased brain in Alzheimer’s disease.
The leading hypotheses have been narrowed down to amyloid plaque deposition and
neurofibrillary tangles (NFTs). In the disease itself, the formation of NFTs strongly
correlates with cognitive dysfunction, whereas amyloid plaque deposition does not produce
cognitive dysfunction alone. Briefly, it has been studied and reported in a transgenic mouse
model that tau phosphorylation plays an important and beneficial role in learning and
memory and that only when tau becomes hyperphosphorylated does the cognitive decline
15

associated with AD and dementia begin (Boekhoorn, Terwel et al. 2006). A study
published in the Journal of Neurochemistry in 2008 studied the temporal correlation
between memory deficits and the activation of glycogen synthase kinase-3β (GSK-3β),
which is a major kinase involved in tau phosphorylation and APP phosphorylation. The
phosphorylation of these proteins facilitates the onset of the two major AD pathologies
described above. The authors induced memory deficit and GSK-3β activation using
WT/GFX, which has already been shown to induce spatial memory loss, and observed a
time dependent correlation with GSK-3β activation and memory deficit (Wang, Zhang et
al. 2008). Also, there was an increase in tau hyperphosphorylation that correlated with the
memory deficit, but amyloid plaque deposition was not changed. Further, the amyloid
plaque deposition increased after the memory deficits were regained by the injected mice.
In this situation, these data suggest that tau hyperphosphorylation may be more important
in AD-like memory deficits.
As stated above, the phosphorylation and dephosphorylation of tau is a normal
process in cell function and is important in microtubule assembly/disassembly and axonal
transport. If this process is natural to the living cell, then something must alter kinase and
phosphatase functions involved with tau regulation. In another study, the authors sought to
determine how tau might become hyperphosphorylated. They showed that aberrant
glycosylation of tau proteins results in their becoming better substrates for major kinases
involved in AD, such as CDK-5 and GSK-3β. The more efficient enzyme-substrate
kinetics involved in tau hyperphosphorylation seems to be a possible answer because the
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increase in tau phosphorylation does not correlate with an increase in CDK-5 and GSK-3
expression in AD brains.
Amyloid plaque formation is a somewhat ambiguous pathological hallmark but it is
believed to be heavily involved in AD progression. There have been many studies showing
that amyloid plaque formation occurs ahead of dementia and cognitive decline but this may
be due to the eventual collapse of neurotrophic factors in the brain, including amyloid
degrading enzymes and glial activation to remove the accumulated proteins. Also, the
formation of amyloid does not always result in AD and may not even exert any form of
mild cognitive impairment throughout the lifetime of affected individuals. But, the fact still
remains that the presence of extracellular plaques disrupt neuronal synaptic connections
and can induce a chronic inflammatory response, a situation in which neurotoxic
chemokines and cytokines destroy neurons and their connections in the affected areas.
Presenilin 1 is a subunit of the gamma secretase complex which facilitates amyloid
processing into insoluble fragments that aggregate into the amyloid plaques. Genetic
inactivation of the PS1 subunit in transgenic mice resulted in a substantial decrease in Aβ
peptides and plaque formation (Saura, Chen et al. 2005). This in turn, resulted in a brief
rescue in spatial memory and learning. However, the rescue in cognitive effects only
occurred temporarily in short term PS1 inactivation as opposed to long term inactivation
(Saura, Chen et al. 2005). Interestingly, there is increasing evidence that other biological
systems are heavily involved in AD progression other than the usual players (i.e. PS1,
APP, secretases, etc.) The tumor necrosis factor death receptor 1 (TNFR1) has been
implicated in the regulation of BACE1 and thus regulates amyloid plaque deposition. He et
17

al.used mice lacking the TNFR1 receptor and showed that the amount of plaque generated
was significantly reduced. In correlation with the decrease in Aβ, the learning and memory
deficits usually attributed to mice in an AD model were prevented and rescued (He, Zhong
et al. 2007). This evidence further supports the suggestion that amyloid protein generation
is the main cause of memory and learning deficits associated with AD. So, if the amyloid
protein seems to be relevant to the issue of memory and cognitive deficits, although this is
not proven yet, it is vitally important to know how and why this is occurring as opposed to
just what is causing it. It has been proposed that the reason amyloid plaque deposition does
not correlate well with cognitive decline is because the deposited plaque is less of a threat
to synaptic connections than soluble Aβ-derived oligomers and also, the memory
impairments can occur before any amyloid plaque deposition is observed. Briefly, the best
correlation for AD related dementia is to observe the synaptic density and to compare it
with non diseased brains and it is this loss in synaptic density explains the memory loss
seen in AD patients. Lacor et al provided evidence to support the idea that the soluble
oligomers of APP can initiate neurotoxic mechanisms in cultured neurons, and thereby
result in abnormal and dysfunctional dendritic spines in the synapse. The authors used
highly differentiated hippocampal pyramidal neurons and exposed the soluble Aβ
oligomers to them. The results were that less expression of memory-related receptors, such
as NMDA, occurred after exposure and that the dendritic spine morphology began to
resemble spines seen in other cognitive related diseases (Lacor, Buniel et al. 2007). In
addition, a study of all-trans retinoic acid (ATRA) as a potential therapeutic for treating
AD has shown that ATRA can attenuate amyloid plaque deposition by inhibiting cdk5 and
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BACE1, both heavily involved in APP processing (Ding, Qiao et al. 2008). The inhibition
of cdk5 and GSK-3β also results in the decerease in tau hyperphosphorylation at multiple
epitopes. In the Morris water maze test of the treated mice, the spatial memory deficits
were comparable to those of wildtype, while the untreated APP/PS1 mice displayed a
profound loss of memory and no ability of spatial memory retention. These results suggest
the idea that although tau hyperphosphorylation and amyloid plaque deposition have
different etiologies, they are both significantly connected in AD. Treatment in the future is
almost certain to combine some form of control over kinases involved, thus allowing a
measure of control over both tau aggregation and APP processing.

Genetics of Alzheimer’s disease
There are two forms of AD; early onset, also known as familial AD (FAD), and late
onset AD (LOAD). FAD occurs in less than five percent of the cases of AD, whereas lateonset comprises the majority of AD cases. Both forms share very similar characteristics
such as plaque formation, NFT formation, and similar distribution throughout the brain
even though the genetics involved are as different as night and day. Since the
groundbreaking achievement of mapping the human genome, it has become ever clearer
that genetics play an important role in the onset of Alzheimer’s disease, especially familial
AD. The human genome consists of roughly 30,000 genes. Within these genes, there are
sequences of nucleic acids that contain the instructions to create proteins. Any alteration or
mutation in this sequence can cause abnormal proteins to form and over time the build up
of these abnormal proteins can cause disease. The genes involved with AD pathogenesis
19

are prevalent in early onset AD (familial AD) and manifest as an autosomal dominant form
of inheritance. In familial AD cases, identification of the genes involved was narrowed to
three: amyloid precursor protein (Goate, Chartier-Harlin et al. 1991), presenilin 1
(Sherrington, Rogaev et al. 1995), and presenilin 2 (Levy-Lahad, Wasco et al. 1995).
Mutations in these genes have been confirmed to intiate APP processing at an earlier age
and have come to be known as Swedish mutations, referring to the people whom these
genes were identified from. Although the discovery of these three genes were
indispensable in furthering the etiology of AD, more and more evidence has pointed to a
myriad of effects that contribute to late-onset AD which comprises almost 95% of all AD
cases. In late-onset AD, the overexpression of APOE ε4 has been shown to be linked to a
four-fold increase in developing AD (Strittmatter, Weisgraber et al. 1993). This gene is
heavily involved with cholesterol levels and consequently, incidences of heart disease are
also increased with the increase in risk of AD.
Figure 5 describes the APP gene on chromosome 21. Mutations in the APP gene
can result in cleavage and accumulation of the abnormal Aβ peptide which will lead to
aggregation and formation of toxic neuritic plaques. It is also interesting to point out that
aberrant expression of chromosome 21 (i.e. Trisomy 21, Down syndrome) in patients
reveal a development of pathological hallmarks associated with AD. These include
amyloid plaques, NFTs, and neuronal loss. The deposition of amyloid plaques occurs at an
early age in Down syndrome patients and in late-onset AD patients, which further supports
the notion that Aβ deposition precedes and may enhance other pathological changes.
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Figure 5 Schematic drawing of APP and Aβ. The vertical dashed lines represent the single membrane
spanning domain and the Aβ domain is represented by the solid black box. The lower drawing shows the
amino acids of Aβ domain with the cleavage sites.
(figure from http://www.scielo.cl/fbpe/img/rmc/v129n5/img14-01.gif)

Inflammatory Hypothesis
In most cases, the early symptoms of AD manifest through subtle losses in short
term memory and gradually progress to total inability to recall any memory and dementia.
What is interesting is that the formation of NFTs and amyloid plaque deposition do not
account for every symptom associated with AD, especially in the early stages where
neurodegeneration is not evident (Heneka and O'Banion 2007). One important facet of AD
is the undisputed changes in inflammatory mechanism in the CNS that have been shown to
facilitate the progression of AD symptoms. While it is true that all aging brains show signs
of neuroinflammation, the diseased brain exhibits a much more profound case of activated
21

glial cells and inflammation (Heneka and O'Banion 2007). Amyloid plaques are diffusely
covered with activated microglia and astrocytes. These glial cells, when stimulated, release
several pro-inflammatory cytokines, chemokines, and complement that include TNF-α, IL1β, and various free radicals (Griffin, Sheng et al. 1998). While the initial inflammatory
response to foreign antigens and wound healing changes are an important component of
CNS health, the chronic overstimulation and activation of the glial cells contributes to
neuronal dysfunction. Once these stimulators of glial cells begin, it creates a perpetual
cycle of neuronal death that is difficult to impede (Abbas, Bednar et al. 2002)( Figure 6).
In brief, it has been reported that fibrillar Aβ interacts with the lipopolysaccaride receptor,
CD14, which causes the cell to secrete proinflammatory cytokines that in turn activate
resident microglial cells in the brain (Fassbender, Walter et al. 2004) (Yan, Zhang et al.
2003). Even more compelling is the report that microglia can kill neurons damaged by Aβ
in a CD14 dependent process (Bate, Veerhuis et al. 2004). There is still much more work
to be done in elucidating the exact mechanisms involved with immune system activation
and response in relation to amyloid plaques because the role of fibrillar versus non-fibrillar
Aβ and other forms have not been completely characterized. But, the significance of a
specific receptor involved with Aβ signaling represents strong evidence that the innate
immune response is an important player in the progression of AD.
Microglia are the resident macrophages within the CNS and play an important role
in quick responses to foreign antigens, tumor invasion, and other forms of tissue injury.
Representing roughly 10% of all cells in the CNS, they become activated and migrate in
and around damaged cells to remove cellular debris and other protein fragments, such as
22

Aβ, through phagocytosis (Fetler and Amigorena 2005) (McGeer, Itagaki et al. 1988). In
the case of AD, it has been shown that products of APP processing can activate glial cells
and if this processing is inhibited, there is a corresponding decrease in glial activation
(Schubert, Morino et al. 2000). As previously stated, the initial activation of microglia
represents the body’s reaction to a neurotoxic stress, and the microglia’s ability to clear Aβ
through phagocytosis is beneficial in that plaque deposition may be reduced (Yan, Zhang
et al. 2003), although Landreth et al has shown that the same receptors responsible for
phagocytosis cause super-oxide damage (Koenigsknecht and Landreth 2004) which
contributes to neurotoxicity. Further, if chronically over activated, the constant release of
cytokines initiates a perpetual cycle of neuronal death that will eventually overwhelm and
destroy neuronal cells. This is the aspect of inflammation that is the target of therapeutics.
If the chronic inflammatory state can be inhibited, then perhaps the beneficial aspects of
microglial clearance and degradation can be enhanced and tip the balance of amyloid
accumulation into a less damaging case.
Similar to microglia, the astrocytes have been shown to be able to clear amyloid
plaques as well as provide neurotrophic support to neurons (Koistinaho, Lin et al. 2004)
but this area is still debatable. They become over activated as well in a chronic
inflammatory state. As is the case in microglia, it is not definitive that amyloid plaque
deposition alone is enough to initiate this inflammatory response because it has been
shown that activated astrocytes can occur in AD brains in the absence of amyloid
deposition (Nunomura, Perry et al. 2001) since they respond to any neuron damage
(Damiani and O'Callaghan 2007). Much work is being done now to discern the true cause
23

of glial activation in AD brains and whether or not this initiates APP processing or vice
versa.
The human immune system is a complex network of mediators. The system as a
whole must be taken into account when trying to deduce a mechanism of neuronal toxicity.
Chemokines, cytokines, and other mediators such as complement can exert beneficial as
well as detrimental effects on the CNS. For example, cytokines such as TNF-α and IL-1β
have been shown to be able to suppress long term potentiation (LTP), a key process in
memory formation, without damaging the neurons structurally (Tancredi, D'Antuono et al.
2000). Neurons communicate via chemical neurotransmitters in the synapse, and this is
believed to be the underlying basis for memory formation. Although the mechanisms are
still being worked out, LTP functions by strengthening synaptic connections which can
strengthen and retain learning and memory skills. This clearly shows how mediators of
inflammation may exert the detrimental effect well before any sign of neuronal loss is
observed (Heneka and O'Banion 2007). It is a balance of these molecules that is desired to
create a “homeostatic” state where the body eliminates toxic antigens and promotes
neuronal integrity. Inflammation is a key process in AD pathogenesis; there is more
inflammation in the AD brain than in a patient after knee replacement surgery. Interference
in the process of glial activation is a novel target of drug therapeutics. Although it does not
attack the amyloid deposition directly, it could be beneficial in halting the
neurodegenerative aspects of AD by promoting effective clearance and degradation of Aβ.
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Figure 6 Diagram showing the perpetual “death” cycle initiated by activated microglia or neuronal damage.
Intervention in this cycle is a therapeutic strategy that has been shown to alleviate neuronal damage and
cognitive deficits associated with it.
(from Block et al. Nature Reviews Neuroscience 8, 57 69 January 2007)

Triptolide
The drug being tested in this study is a major constituent of the Chinese herb,
Tripterygium wilfordii Hook F, called Triptolide. It is a diterpenoid triepoxide and has
structural similarities with steroids (see figure 7). The rationale for choosing such a drug
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can be traced to previous studies involving Triptolide being used to treat rheumatoid
arthritis, an inflammatory disorder, and some cancers through its antiangiogenic properties
(He, Liu et al. 2009). With the recent discovery that Alzheimer’s disease brains display
aberrant expression of cell cycle related proteins such as the cyclin-dependent kinases
(CDKs), it was hypothesized that the use of anti-cancer drugs may have some effect in
alleviating AD symptoms or even attenuates some pathology, including APP processing.
For instance, treatment of APP/PS1 mice with indirubin, another Chinese herbal medicine
for cancer, had alleviated AD pathologies including Aβ plaque load. It was later discovered
through X-Ray crystallography that indirubin can bind to and inhibit CDK-2, eliminating
its effects from over expression in diseased neurons. In the literature, Triptolide has been
reported to suppress inflammation and cartilage destruction, inhibit prostaglandins via
inhibition of cyclooxygenase (COX)-2, and reduce nuclear factor kappa B(NFκB)
expression in vivo (Lin, Liu et al. 2007). Triptolide has also been shown to inhibit the
growth and metastasis of solid tumors through apoptosis induction and the reduction in
expression of several cell cycle related molecules (Yang, Chen et al. 2003). In this same
study, it proved to be more effective than conventional anti-tumor drugs such as
adriamycin and cisplatin at inhibiting tumor cell proliferation. One of the most important
effects of Triptolide related to Alzheimer’s disease was reported in 2008 in the Journal of
Neuroimmunology. Triptolide inhibited the production of tumor necrosis factor-α (TNF-α)
and interleukin-1β (IL-1β), both inflammatory cytokines known to be produced upon
amyloid-β1-42 stimulation of neuronal cells (Jiao, Xue et al. 2008). This role of Triptolide is
important because it is believed that the progression of Alzheimer’s disease can be halted if
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chronic activation of the neuronal glial cells such as microglia and astrocytes can be
inhibited or reduced. Previous work in this laboratory has tested many other Chinese
herbal anti-cancer agents and some experimental agents developed for specific inhibition
of certain neural processes. These include retinoic acid, a metabolite of vitamin A,
indirubin, lupeol, both anti-cancer agents, and the CXCR-2 antagonist SB225002. CXCR-2
is a chemokine responsible for many inflammatory mechanisms in the CNS. All of these
drugs so far, have been proven to be beneficial in attenuating AD pathologies, such as APP
processing and tau hyperphosphorylation, and able to rescue memory deficits in our AD
mouse model as evidenced in the Morris Water maze acquisition test. The dose of 40µg/kg
was decided as the appropriate dose to administer to the mice after carefully searching the
literature and finding a study that administered varying concentrations of Triptolide to
mice in order to discover its effects in arthritis (Lin, Liu et al. 2007). The effects of
Triptolide were most prominent at a concentration of 32µg/kg. This corresponded to 0.6252.5% of LD50 for Triptolide (1.278mg/kg). There was no evidence of drug toxicity and no
viscera damage. Even more, several studies characterizing the pharmacological toxicology
of triptolide in mice indicated a safe dose as 0.03 mg/kg (Xu, Pan et al. 2008). Triptolide
can cross the blood brain barrier fairly easily due to its lipophilic character and size (Wang,
Liang et al. 2008).
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Figure 7 Structure drawing of the triptolide molecule. Its four rings are homologous to corticosteroids, thus,
it has similar effects in immunosuppression.

(figure from http://www.asiaandro.com/1008-682X/1/121f1.jpg, Wang et al, 1999)

Figure 8 Mechanisms of the neuroprotective effects of triptolide. Overactive microglia in the CNS can lead
to chronic release of cytokines and other inflammatory mediators which can kill dopaminergic neurons.
Triptolide, aka T10, can inhibit the overactivation of microglia resulting in inhibition of the release of
inflammatory cytokines, free radicals, NO, and Ca2+ overload.
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(figure from Wang, Liang et al 2008)
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Materials and Methods

Transgenic Mice and Triptolide treatment. There are many different mouse models
available for the study of Alzheimer’s disease. For this study, we utilized APP/PS1 doubletransgenic mice from The Jackson Laboratory [strain name, B6C3-Tg (APPswe,
PSEN1dE9)85Dbo/J; stock number 004462]. This particular strain of mice expresses a
mutant chimeric mouse/human APP gene with Swedish mutations at K595N/M596L sites.
There is also a presenilin 1 (PS1) human mutant with the exon 9-deleted variant. This
variant is under the control of mouse prion promoter elements that directs the expression of
these transgenes mainly to neurons of the CNS. The APP/PS1 mice were maintained as
double hemizygotes by cross breeding with wild-type mice with a background strain of
B6C3F1/J (stock number 100010), also from The Jackson Laboratory. To ensure proper
genotype before each study, tail biopsies and PCR analysis of genomic DNA were
performed. All animals were housed in the animal care facility at Virginia Commonwealth
University medical campus and are in accordance with standard animal care protocols.
Five month old wild-type mice and APP/PS1 mice were randomly assigned into four
groups: untreated wild-type mice, treated wild-type mice, untreated APP/PS1 mice, and
treated APP/PS1 mice. The treated groups received 40µg/kg of the drug Triptolide (Sigma,
T3652), which was dissolved in normal saline with 5% DMSO in saline (vehicle). They
were injected intraperitoneally three times weekly at 40µg/kg. The control groups received
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an equal volume of 5% DMSO. Treatment of drug and vehicle control lasted
approximately 8 weeks. The dose and regimen of treatment were based on previous reports
describing effective therapeutic doses using Triptolide in mice and characterization of the
pharmacokinetics involved (Blanchard, Moussaoui et al. 2003; Lin, Liu et al. 2007). The
rationale for starting drug treatment at 5 months of age is based on previous reports that
APP/PS1 mice of this particular strain begin to accumulate Aβ plaques as early as 5
months of age. Although the expression of the mutant forms of these genes do not
necessarily accurately describe the cases in sporadic late-onset AD, the lesions seen in all
cases point to a final common pathway of pathologies that all sufferers of AD develop,
human or mouse.

Morris water maze test. After the treatment with Triptolide for 8 weeks, the memory and
spatial learning was evaluated using the Morris water maze test (Morris 1984). The maze
itself consists of a 120 cm diameter X 50 cm height circular and galvanized water tank.
The area of the tank was divided into four equal quadrants and made opaque by the
addition of milk powder. The water temperature was adjusted to 24 ± 1°C. An escape
platform of 10 cm diameter was placed in one of the quadrants and submerged 2 cm below
the water surface and at least 30 cm away from the side wall. Throughout the experiment,
the platform was kept in the same quadrant. The mice were each gently placed in the maze
always facing the tank wall, and were required to find the platform using only distal spatial
cues in the testing room. For each trial, a different starting position was used. The mice had
120s to find the platform and once they found it they were allowed to remain on the
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platform for 10s. Then, the mice were taken out, dried, and placed in a separate cage for
~60 minutes before the next trial. If a mouse failed to find the platform within the allotted
120s, the experimenter assisted the mouse and subsequently allowed to stay on the
platform for 10s. Between the trials, the water was stirred to erase olfactory traces of the
previous mice. Each animal was trained for four trials per day for five consecutive days to
locate and escape onto the platform. Their spatial learning scores was measured as escape
latency in seconds and recorded after each trial. In order to assess the memory
consolidation, a probe trial was conducted two days after the five day acquisition tests.
During this trial, the platform was removed and the mice were allowed to swim freely in
the tank. Time spent in the quadrant that had the platform during the acquisition tests was
taken to indicate the degree of memory consolidation. All time measurements were done
using a stopwatch by an experimenter blinded to which experimental group to which each
animal belonged.

Immunohistochemistry. After testing the spatial and learning memory of the mice, the mice
were anesthetized with an intraperitoneal injection of ketamine (0.05 mg/kg) and perfused
with PBS and subsequently 4% paraformaldehyde in PBS. The brains were removed and
placed in 70, 96, and 99% ethanol solutions, respectively, for 2 hour intervals in order to
dehydrate the brains completely. The brains were then left in xylene overnight and
subsequently embedded in paraffin. The paraffin blocks were then sectioned horizontally
by a microtome at 10µm. The sections were placed in a warm water bath and mounted onto
SuperFrost Plus (Menzel-Glazer) glass slides. Sections were placed in 40° C for one hour
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before being rehydrated and stained. Procedures for immunohistochemical staining were
performed using coronal brain sections. The sections were deparafinned, rehydrated in
various intervals of xylene and ethanol, and endogenous peroxide quenched with hydrogen
peroxide [1% (v/v) in methanol]. They were then placed in 10mM sodium citrate buffer
(pH 6) and microwaved for 15 minutes. After cooling to room temperature, they were
incubated in blocking buffer [10% (v/v) goat normal serum (Millipore Bioscience
Research Reagents) in PBSA containing 0.1% (v/v) Triton X-100 (Sigma)] for 60 minutes.
Adding the appropriately diluted antibodies overnight at 4° C followed the blocking.

Histochemistry. The paraffin-embedded brain sections were first deparafinned and
rehydrated in various xylene and ethanol solutions following this protocol: 15 minutes
xylene I; 15 minutes xylene II; 5 minutes 100% ethanol; 5 minutes 100% ethanol; 5
minutes 95% ethanol; 5 minutes 85% ethanol; 5 minutes 70% ethanol; 5 minutes 50%
ethanol; 5 minutes 30% ethanol; store in deionized water until ready for development.
Subsequently, the sections were stained for the presence of Aβ plaque deposits using the
Campbell-Switzer silver staining method (NeuroScience Associates). A detailed protocol
for using this stain was generously provided by Dr. Bob Switzer of NeuroScience
Associates in Knoxville, TN. The procedure begins after the rehydration of the brain
sections by placing the sections in 2% ammonium hydroxide solution and shaking for 5
minutes then placing in deionized water for 1 minute twice. Then, the sections are covered
and placed in the SPC solution, a pyridine silver solution for the induction of nucleation
sites, for 40 minutes while gently stirring. After the 40 minutes, the sections are placed in
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1% citric acid solution for 3 minutes while shaking. Subsequently, the slides are placed in
4.99 pH acetate buffer while the developing solution is prepared. The developing solution
consists of making three separate solutions and then mixes them together to form the ABC
solution. Solution A consists of 5g of sodium bicarbonate dissolved in 100mL of deionized
water. Solution B consists of 0.2g of ammonium nitrate, 0.2g of silver nitrate, and 1.0g of
silicotungstic acid all dissolved in 100mL of deionized water. Solution C consists of taking
20mL of solution B and adding 140µL of 37% formaldehyde. All three solutions are mixed
and stirred well. This ABC solution is then added to the brain sections, making sure to
completely cover the brain tissue, and then incubated at room temperature until the plaques
are developed. Once the desired results are obtained, the brain slides are washed in 4.99pH
acetate buffer for 3 minutes. They are subsequently washed in deionized water for 30
seconds, then a 0.5% thiosulfate buffer for 45 seconds, and then deionized water again for
2 minutes. The slides are then available for additional staining or to be mounted.

Image Analysis: Images for the DAB staining and Campbell-Switzer staining were taken
with a Nikon TE2000-E inverted microscope, whereas immunofluorescent images were
aquired with a Nikon TE2000-U confocal microscope under 40x oil immersion objective
with numerical aperture (NA) 1.4, zoom 1.6. Fluorochromes were excited using a 488nm
argon laser for FITC and a 543 nm helium-neon laser for Cy3, and the detector slits were
configured to minimize any crosstalk between the channels.
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Stereology: The stereological setup consisted of an Olympus BH-2 microscope (Olympus
Life and Material Science Europe) with a high numerical aperture (NA 1.40) and oil
immersion 100x objectives. This allows focusing in a thin focal plane inside a thick
section. A camera transmits the image to a monitor on which a counting frame is
superimposed using the computer-assisted stereological CAST-GRID software
(Visiopharm). A motorized automatic stage was used to control movement in the x-y plane
via a connected joystick. Movement in the z axis was done manually with the focus button
on the microscope, and the distance between the upper and lower surfaces of the section
and the height of the dissectors were measured with a Heidenhain microcator (model VRZ
401) with a precision of 0.5 µm. The number of Aβ plaques in the hippocampal and
cortical regions were counted using the optical fractionator method of unbiased
stereological cell counting techniques. Aβ plaques or cells were sampled in counting
frames of 644-988 µm2 [a(frame)] moved in x and y steps of 100 x 100 µm [a(step)]. The
area sampling fraction (asf) was calculated as a(frame)/a(step). The thickness sampling
fraction (tsf) was calculated as the height of the optical dissector probe (h) (8 or 10 µm)
divided by the average height of the sections (t) (tsf=h/t). Aβ plaques were counted using a
20x immersion lens. Total Aβ plaque or cell number (,) was estimated using the following
equation: ,=Q- x 1/tsf x 1/asf x 1/ssf, where Q- is the number of cells counted, and ssf is
the section sampling fraction. In the case of clusters of Aβ plaques, each cluster was
counted as one plaque or cell and identified by the most clearly defined nucleus.
Coefficients of error and variation were calculated as described previously (Wirenfeldt,
Dalmau et al. 2003). The same sections that were sampled for number estimates were used
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to estimate volume of Aβ plaques in cortical or hippocampal regions. The system software
superposed a point grid at random over low-power (2.5x) magnified images of each
section. Total reference volume (Vref) was estimated using the Cavalieri-point counting
method (Gundersen and Jensen 1987), based on the sum of points that hit on each
reference space, a(p) is the area per point on the grid, t is the mean section thickness (in
millimeters), and k is the sampling interval. The same a(p) was used for estimating volume
for both the cortical and hippocampal regions. The densities of Aβ plaques (number per
cubic millimeter) were calculated by dividing the number counted by the total volume
sampled of each reference space. The volume of sampled reference space was the number
of dissectors multiplied by the volume of one dissector.

Western blot analysis. Brain tissues were homogenized in TBS (20mM Tris-HCl buffer,
pH 7.4, 150mM NaCl) containing several protease inhibitors such as, 0.5mM
phenylmethylsulfonyl fluoride, 20µg/mL aprotinin, 20µg/mL leupeptin, 20µg/mL
pepstatin, and 1mM EDTA. Approximately, there was 0.150g of brain tissue per 2 mL of
TBS buffer. The brain homogenates were briefly sonicated and subsequently centrifuged at
15,000 x g for 30 minutes. In order to determine protein concentration, the BCA protein
assay (Pierce) was performed. The assay results were then used to determine proper
loading amount. For each gel, 10µg of brain SDS supernatants were loaded in each well
and run on 12% SDS polyacrylamide gel. The proteins were transferred at 300mA for 2
hours to a polyvinylidene difluoride membrane (BioRad). After transfer, the membranes
with the newly aquired proteins were incubated for at least 4 hours or overnight in 4°C
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with specific antibodies to the proteins of interest. After incubation, the membranes were
washed twice in 0.1% tween 20/TBS for 5 minutes. Subsequently, the membranes were
then incubated at room temperature with the corresponding HRP-labeled secondary
antibody for 1 hour (concentration always 1:2000). The ECL system was used for
detection of labeling (GE Healthcare). This entailed placing radiographic film over the
exposed membrane in a dark room and then developing it in a Kodak film developer. To
ensure equal loading, β-actin antibody was used in the same procedure outlined above at
concentration of 1:5,000. The observed bands were then analyzed using densitometric
software (Scion Image). The following antibodies were used for western blot analysis:
rabbit polyclonal anti-phosphorylated (p)-CDK5 (Ser 159) (1:500; Santa Cruz
Biotechnolgy), mouse monoclonal anti-CDK5 (1:500; Santa Cruz Biotechnology), rabbit
polyclonal anti-p-tau (Ser 404) (1:300; Santa Cruz Biotechnology), rabbit polyclonal antip-GSK3β (Ser 9) (1:500; Santa Cruz Biotechnology), rabbit polyclonal anti-p-GSK3α/β
(Tyr 279/Tyr 216) (1:500; Santa Cruz Biotechnology), rabbit polyclonal anti-GSK3β
(1:500; Santa Cruz Biotechnology), mouse monoclonal anti-p-APP (Thr 668) (1:500; Cell
Signaling Technology), rabbit polyclonal anti-APP-C-Terminal Fragments (CTFs)
(1:3000; Sigma), mouse monoclonal anti-β-actin (1:5,000; Sigma), mouse monoclonal
anti-GFAP (1:500; DakoCytomation).
Iba-1, BACE1, PS1

Statistical analysis. Presented data are expressed as the mean ± SEM and the analyses were
performed using a two-way ANOVA followed by Fisher’s least significant difference post
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hoc analysis to identify effects deemed to be significant. Differences were deemed
significant at p < 0.05.
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Results

Triptolide treatment prevents Aβ plaque accumulation in APP/PS1 mice
Triptolide has been shown in the literature as a potent therapy for many cancers and
rheumatoid arthritis but the effects on amyloid accumulation in APP/PS1 mice has not
been characterized. After administration of triptolide intraperitonneally for 8 weeks on 5
month old APP/PS1 mice and wild type littermates, the results in figure 9 show that
triptolide treatment substantially decreased the amount of Aβ plaque accumulation in
APP/PS1 mice compared to vehicle treated APP/PS1 mice. The areas observed include the
frontal cortex and the hippocampus, a region that is involved in memory and learning.
Stereological analysis also portrays a significant decrease in the amount of Aβ plaque
levels. Plaque number, average volume, and area occupied by the amyloid plaques were all
reduced in both the frontal and hippocampal brain regions of the APP/PS1 mice. Also, the
vehicle treated APP/PS1 mice had no significant effects when compared to untreated mice
of the same genotype and age (data not shown). These results support the idea that
triptolide may be a possible therapeutic agent for inhibiting amyloid plaque deposition. A
caveat to these results is that out of three samples subjected to amyloid staining and
stereological analysis, one set of samples did not show a decrease in Aβ levels, but rather
an increase in plaque accumulation. The reason for the antithetical result has yet to be
determined.
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Triptolide does not inhibit APP processing
The current knowledge of amyloid processing indicates that APP plays a central
role in the pathogenesis of plaque accumulation. APP CTFs are an early biomarker for the
diagnosis for AD (Sergeant, David et al. 2002) and are a key step in the processing of APP.
Western blot analysis using an anti-CTF antibody was used to determine whether APP was
affected by the treatment with triptolide. This particular antibody recognizes the full-length
APP protein as well as the CTFs. As shown in figure 10, we observed that APP expression
is not changed between vehicle and drug treated mice. Interestingly, the CTFs were
enhanced in the triptolide treated mice when compared to wild type. Also, the vehicle
treated APP/PS1 mice did not show a significant difference in APP or CTF expression
when compared to untreated mice of the same age (data not shown). To further explore the
affects of triptolide on APP processing, an anti-BACE1 antibody was used to see whether
the beta secretase enzyme was differentially expressed. Based on the western blot data in
figure 10, it appears that BACE1 levels were not altered between the drug and vehicle
treated groups. In keeping with the exploration of APP processing, an anti-phospho-APP
antibody was used to see if the phosphorylation of the APP protein was affected in the
drug treated mice. The phosphorylation of APP at Thr668 is important in the processing of
this protein to cleavage and Aβ oligomer formation (Lee, Kao et al. 2003) and
neurodegeneration (Chang, Kim et al. 2006). Again, as shown in figure 10, no significant
change was seen across the group. The role of hyperphosphorylated tau is important when
considering the clinical manifestations of AD. In this study, it was particularly difficult to
obtain data that was consistent in showing whether tau was hyperphosphorylated or not.
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Consequently, no data is presented that shows tau hyperphosphorylation in the APP/PS1
mice even though it has been well documented that these mice exhibit excessive
phosphorylation at several tau epitopes (Kurt, Davies et al. 2003). Nevertheless, according
to the amyloid hypothesis, the role of tau hyperphosphorylation in relation to memory loss
appears to occur downstream of plaque formation and deposition which leads many to
believe that its role in neurodegeneration is secondary to amyloid processing. This is,
however, a very much debatable area in AD research and it should be emphasized that
there is no definite consensus on how the mechanistic cascade of AD plays out. Kinases
known to be implicated in AD include CDK5 and GSK3β. These are involved in tau
hyperphosphorylation (Singh, Grundke-Iqbal et al. 1994; Hartigan and Johnson 1999) and
APP phosphorylation (Aplin, Gibb et al. 1996; Iijima, Ando et al. 2000). According to
figure 10, observing the activity of CDK5 and GSK3β, we can conclude that the
administration of triptolide has no effect on the enzyme activity or expression levels. The
expression remained unchanged between drug treated APP/PS1 mice and vehicle treated
APP/PS1 mice. Assessing the activity of GSK3β, the results were similar to that of CDK5.
The levels of protein expressed in drug treated versus vehicle treated APP/PS1 mice were
unchanged, indicating that triptolide has no effect on changing the activity of GSK3β.
Together, the data concludes that the activities of the major kinases of tau and APP
processing are unchanged by triptolide treatment.

Triptolide treatment reduces the number of glia associated with Aβ plaques in
APP/PS1 mice
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It has been well documented that APP/PS1 mice as well as AD patients exhibit
enhanced reactivity of glial cells such as microglia and astrocytes. These glial cells are in
and around Aβ plaques and appear to be the results of an inflammatory reaction caused by
these diffuse plaque depositions. This is very characteristic of inflammatory mechanisms
that occur when injury presents itself in the brain (McGeer and McGeer 1999). Triptolide
has been shown in vitro to inhibit inflammatory cytokines such as IL-1β and TNF-α in
response to amyloid oligomer stimulation (Jiao, Xue et al. 2008). The activated microglia
was visualized by immunohistochemical techniques using an Iba-1 antibody. Double
staining of Iba-1 and amyloid plaques shows that activated microglia are localized in and
around the deposited plaques. In figure 11, there is a significant increase in Iba-1
immunoreactivity around the amyloid plaque in the vehicle treated APP/PS1 mouse brain
as compared to the triptolide treated APP/PS1 mouse brain. However, it is difficult to
determine if the amount of microglial cells in the drug treated APP/PS1 mouse brain is the
result of a significant inhibition by triptolide or from the significant decrease in Aβ plaque
deposits.
The activated astrocytes were visualized using immunohistochemical techniques
using a GFAP antibody. Similar to the microglia, the double staining of astrocytes and Aβ
plaques showed that the astrocytes indeed were in and around the plaque deposits. The
amounts of activated astrocytes around the plaques were significantly reduced in the
triptolide treated APP/PS1 mouse brain when compared to the vehicle treated APP/PS1
mouse brain. This is similar to the microglia results but similar conclusions cannot be
drawn from the data since astrocyte migration activity differs from microglia (Pihlaja,
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Koistinaho et al. 2008). Thus, it is still unclear whether the reduction in glial activation is a
result of triptolide’s action as an immunosuppressant or from the substantial decrease in
amyloid plaques.

Triptolide treatment rescues learning and memory deficits in APP/PS1 mice
The mouse model used in this study was an APP/PS1 double transgenic mouse line
that is well characterized. This model has been consistently reported to develop Aβ plaques
associated with cognitive deficits as the mice age (Trinchese, Liu et al. 2004). Based on the
Morris water maze test, the results of our investigation in figure 12 show that after
treatment with triptolide, the APP/PS1 mice exhibited a substantial improvement in
memory as proven by the decrease in escape latency across trials. Improvement of memory
retention in the drug treated APP/PS1 mice was also evidenced by the probe trial. In
contrast, the data illustrate that the vehicle treated APP/PS1 mice portrayed an inability to
acquire the learning and memory exhibited by wild type and triptolide treated mice. It
should be noted that the deficits in the acquisition and probe trial were not attributable to
different swim speeds since APP/PS1 mice and wild type mice exhibit similar swimming
abilities. Based on these results, it can be concluded that triptolide is beneficial in retaining
cognitive abilities in APP/PS1 mice.
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Figure 9 Triptolide treated APP/PS1 mice show reduced levels of Aβ deposits when compared with
vehicle treated APP/PS1 mice. A represents Campbell-Switzer staining in the frontal cortex of
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APP/PS1 mice treated with vehicle (left) and triptolide (right). B represents Campbell-Switzer staining
in the frontal cortex of APP/PS1 mice treated with vehicle (left) and triptolide (right). C represents
stereological quantification of Aβ plaque number in the hippocampus. D represents stereological
quantification of Aβ volume in the hippocampus, all described in the Materials and Methods. Values
from multiple images of each section were averaged per animal per experiment. Data are mean ± SEM
from three mice per genotype. *p<0.05 versus vehicle treated control APP/PS1 mice.
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Figure 10 Triptolide treatment had no change on the expression of APP and did not reduce the amount of
CTFs. Western blots for APP, APP-CTFs, phosphorylated-APP, BACE1, PS1, phosphorylated GSK3α,β
(Tyr 216), phosphorylated CDK5 (Ser 159), CDK5, and β-actin.
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Figure 11 Triptolide treatment appears to cause a reduction in microglial reactivity in the APP/PS1 mice
brains. A represents Campbell-Switzer staining for Aβ and immunostaining of Iba-1 in the hippocampal CA3
region. Wild-type (WT) and APP/PS1 mice with vehicle or triptolide are shown. There are less activated
microglia in the triptolide treated APP/PS1 mouse brain than in the vehicle treated APP/PS1 mouse brain. B
represents Western blot analysis of Iba-1 expression among the four genotypes. A slight reduction can be
seen in the triptolide treated versus vehicle.
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Figure 12 Triptolide treatment appears to cause a reduction in astrocyte reactivity in the APP/PS1 mice
brains. A represents Campbell-Switzer staining for Aβ and immunostaining of GFAP in the hippocampal
region. Wild-type (WT) and APP/PS1 mice with vehicle or triptolide are shown. There is less activated
astrocytes in the triptolide treated APP/PS1 mouse brain than in the vehicle treated APP/PS1 mouse brain. B
represents Western blot analysis of GFAP expression among the four genotypes. There appears to be no
significant reduction in the triptolide treated brain versus the vehicle treated brain.
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Figure 13 Treatment of APP/PS1 mice with triptolide results in attenuation of AD-type spatial memory
deterioration. A represents acquisition of spatial learning in the Morris water maze hidden platform task.
APP/PS1 mice treated with triptolide displayed learning similar to wild-type mice; while vehicle treated
APP/PS1 mice displayed learning deficits. Latency score represents the time taken to escape to the platform
from the water. Lines represent mean ± SEM from six to eight mice (indicated) per group. B represents the
memory test in the Morris water maze probe trial without the platform. The deficits in the vehicle treated
APP/PS1 mice were improved in the triptolide treated APP/PS1 mice. Error bars represent mean ± SEM from
six to eight mice (indicated) per group. *p< 0.05, **p< 0.01 versus vehicle treated control APP/PS1 mice.
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Discussion

As stated above, triptolide’s therapeutic potential has been exploited for the use in
rheumatoid arthritis and certain cancers. Its structure has similar homology to
corticosteroids and thus is a potent immunosuppressant. This aspect of immunosuppression
is believed to play a beneficial role in the inflammatory mechanisms of AD and help bring
the patient’s immune system to a state of effectively clearing amyloid plaques from the
CNS. This is further supported by several epidemiological studies suggesting a potential
benefit from using anti-inflammatory drugs on AD patients (Akiyama, Barger et al. 2000).
Inflammatory processes in the CNS become detrimental to the AD patient. This is believed
to be caused by activated glial cells that target senile amyloid plaques for degradation but
in the process can damage neurons in and around the plaque deposits. Therefore, a possible
solution for treatment in conjunction with inhibiting plaque formation would be to inhibit
glial cell activation. Certain drugs have shown promise as treatments for AD and clinical
trials are currently being done to study the effectiveness of such anti-inflammatory
treatment. However, the mechanisms of action for this avenue of therapy still remains
elusive since cytokines released from glial cells have neurotrophic as well as neurotoxic
effects (Richartz, Stransky et al. 2005). This study has indicated that treatment of APP/PS1
double transgenic mice with triptolide can attenuate amyloid plaque deposition which
concordantly will halt deficits in learning and memory. It has been reported that the effects
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of anti-inflammatory drugs may not act via inhibition of prostaglandins but actually
reducing the plaque burden on the CNS (Cirrito and Holtzman 2003). The aspect of
cognitive deficits is the chief clinical manifestation of AD and arguably the central target
of any drug therapy. Again, triptolide’s effect on the immune system is a possible
explanation for the halt of neurodegeneration and rescue of spatial learning and memory
exhibited in treated mice. Of the two chief protein aggregates, only amyloid plaque
deposition was observed to have been attenuated by treatment with triptolide. The
Campbell-Switzer stain is a reliable silver stain for amyloid plaques in brain sections.
Expression of the APP protein was not changed among the triptolide treated and vehicle
treated APP/PS1 mice which indicates that triptolide had no effects on APP gene
transcription. However, there was an elevated presence of CTFs, the cleavage products of
alpha, beta, and gamma secretases. This clearly indicates that cleavage of the APP protein
is not hindered and in fact may be enhanced at a specific point along the processing. The
preclusion of plaques from the histological staining of the brain sections of APP/PS1 mice
treated with triptolide can be explained by an enhanced clearance and degradation of
plaque deposits. However, the activity of gamma secretase can also be part of the
explanation since this enzyme is still poorly understood in its function. An enhanced level
of inflammatory mediators in the APP/PS1 mice have been shown to increase BACE1
activity in the hippocampus and result in an increase in CTFs (Blasko, Beer et al. 2004).
Also, gamma secretase has been shown to increase in expression in response to activated
glial cells from brain injury (Nadler, Alexandrovich et al. 2008). In keeping with the idea
that inflammation is heavily involved in the pathogenesis of AD, it should be noted that
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certain benefits can arise from inflammatory mechanisms. This depends on which
mediators are involved, the time the disease develops, and whether the response is chronic
or acute inflammation (Sastre, Walter et al. 2008). Microglia can clear amyloid plaques
through phagocytosis and release elements of neuroprotection such as glia-dervied
neurotrophic factor (GDNF) (Liu and Hong 2003). Interestingly, it has been reported that
microglia already activated from newly formed amyloid plaques can restrict the growth of
the plaques if further activation of microglia is inhibited (Meyer-Luehmann, Spires-Jones
et al. 2008). Since triptolide has been shown to inhibit inflammatory cytokine release, it is
certainly possible that the clearance of amyloid by glial cells and the formation of new
plaques keep each other in “balance” and reach a steady state of formation and clearance.
Further testing would be needed to support the hypothesis of a reduction in microglia
activation with triptolide treatment. With the gamma secretase complex, the situation
becomes even more unclear. A recent study has shown that some anti-inflammatory drugs
can directly modulate the activity of gamma secretase (Czirr and Weggen 2006). The
gamma secretase is composed of four essential membrane proteins: aph-1, pen-2, nicastrin,
and presnilin (PS) (Sastre, Walter et al. 2008). It has been reported that activated glial cells
have an increase in expression of presenilin (Nadler, Alexandrovich et al. 2008) but it is
still unknown whether this can affect the glial cell function. Further, in cases of familial
AD (FAD), where the patient displays amyloid plaques earlier than usual, there is a
positive correlation with an increase in inflammatory processes. Again, it is unclear
whether the increase in presenilin promotes neuroinflammation through other pathways or
whether it promotes neuroinflammation through a substantial increase in amyloid plaque
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deposition (Sastre, Walter et al. 2008). Using figure 7 again, and based on the results of the
experiment, there are a few mechanisms that triptolide could be exploiting in exerting its
beneficial aspects in the APP/PS1 mice. Triptolide is very much possibly interacting at the
specific receptors for microglia activation. It has been shown to inhibit specific cytokine
production and NO production, thereby inhibiting microglial receptor activation. However,
no evidence has shown that superoxide formation is inhibited and this is believed to be of
paramount importance in glial cell activation. The reduction in cytokine production will
also inhibit glutamate and Ca2+ excitotoxicity, as stated in the introduction, and can
therefore reduce cell death. While these mechanisms are plausible for explaining an
inhibition of neuronal cell death, thereby enhancing learning and memory in the APP/PS1
mice, it does not provide an adequate explanation for a reduction in amyloid plaque
deposition.
This study also attempted to investigate the prevalence of tau hyperphosphorylation
among the four genotype mice tested. Unfortunately, the western blot analysis of brain
homogenates yielded conflicting and inconsistent data (data not shown). Therefore, it was
determined that the study would forego any further attempt to assess the reason for this as
it seemed beyond the scope of this project. The absence of any tau hyperphosphorylation
data appears to be inconsequential when measuring the cognitive deficits in the Morris
water maze although many believe that it is closely linked with neuronal damage. It should
be further explored as to why this pathological hallmark of AD did not manifest itself in
these groups of mice or some technological error occurred that is responsible for the
conflicting data. When it comes to the major kinases involved with tau
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hyperphosphorylation (Lovestone and Reynolds 1997), we see that there appears to be no
change between the triptolide treated and vehicle treated APP/PS1 mice. The expression of
total CDK5 remained constant throughout the four genotypes, indicating no change in
expression of the inactivated form of CDK5, phosphorylated CDK5. GSK3 also showed no
change.
Since triptolide has been shown to inhibit inflammatory cytokines and chemokines,
it was expected that glial activation might be reduced in the diseased CNS to a
neurotrophic level. And indeed the APP/PS1 mice treated with triptolide did appear to
exhibit a decrease in glial number in cortical and hippocampal regions. It is unclear
whether the decrease in glial activation is the result of a decrease in Aβ plaque deposits or
whether triptolide’s anti-inflammatory properties inhibited the activation directly.
Microglia change has so many parameters including morphology, number, and cytokine
production. But, the appearance of a decrease in glial number supports an antiinflammatory effect and thus can be beneficial and effective in neurodegenerative
disorders, such as AD.
This study demonstrates that administration of triptolide can reverse or inhibit
spatial learning and memory deficits associated with APP/PS1 mice. The cognitive
dysfunction associated with these mice is a result of an accelerated production of amyloid
plaques and loss of functional synapses (Chen, McPhie et al. 2000). Although it is clear
that triptolide attenuated the amyloid plaque accumulation in brains of APP/PS1 mice
relative to vehicle treated APP/PS1 mice, it cannot be definitively ruled out that triptolide
exerts its neuroprotective effects through other mechanisms. However, a possible solution
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rests with the evidence that triptolide has neuroprotective effects on dopaminergic neurons
which can increase and/or keep intact the ability to release cholinergic neurotransmitters
that can protect against the cytotoxic effects of Aβ (Wang, Liang et al. 2008).
This study has provided evidence that triptolide can inhibit amyloid plaque deposit
and other neuropathologies associated with AD. Also, cognitive deficits associated with
APP/PS1 double transgenic mice were ameliorated. The long historical use of this Chinese
herbal derivative has now been characterized in an AD mouse model and hopefully will
lead to clinical trials where the effects can be further explored in human AD patients.
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Future Studies

The present study has done a lot to answer the question of whether or not triptolide
can be a beneficial therapeutic for treating Alzheimer’s disease. There is a substantial
decrease in amyloid plaque deposits and glial activation. Memory and learning abilities
appeared to be rescued in the drug treated APP/PS1 mice relative to vehicle treated
APP/PS1 mice. Although these are exciting results, the exact mechanism of triptolide’s
effects have not been elucidated. A more extensive study of gamma secretase could
possibly reveal much in how the anti-inflammatory property of triptolide affects its
activities. A more extensive study of the phagocytic ability of microglia in the dystrophic
brain treated with triptolide may provide an answer to how the brain can inhibit the
accumulation of Aβ. This would involve phagocytosis assays and electron microscopy
studies of brain tissue. A thorough assessment of changes in synaptic integrity using
drebrin and synaptophysin markers can provide direct evidence for an inhibition of
neurodegeneration in triptolide treated mice. Further studies of iNOS changes and cytokine
and super-oxide release in relation to AD and triptolide treatment can explain glial
activation mechanisms and anti-inflammatory effects of triptolide. And finally,
administration of triptolide in a much older APP/PS1 mouse model could fully answer the
question of whether triptolide can attenuate and decrease Aβ accumulation. Complications
would likely arise when trying to establish a rescue in memory deficits since neuronal
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death cannot be reversed. Nevertheless, much work remains in fully characterizing
triptolide’s therapeutic affects and the results presented in this study will perhaps further
the study of anti-inflammatory drug therapy, an avenue that has proven to be
neuroprotective and inhibit hallmark pathological symptoms.
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